Co-Diagnostics, Inc. (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia. The expansion includes Bangladesh, Pakistan, Nepal, and Sri Lanka, significantly increasing CoSara's addressable market to an estimated $13.0 billion. This strategic move supports the planned commercialization of the CoSara PCR Pro(R) point-of-care platform and the SARAGENE(R) product line, subject to regulatory approvals.
The expansion allows CoSara to build regional distribution channels and position itself for broader deployment of its molecular diagnostics solutions. By entering these new markets, Co-Diagnostics aims to address the growing demand for accurate and accessible diagnostic testing in South Asia. The region has seen increased focus on healthcare infrastructure and infectious disease management, particularly following the COVID-19 pandemic.
Co-Diagnostics, a Utah-based molecular diagnostics company, develops, manufactures, and markets state-of-the-art diagnostics technologies. Its technologies are utilized for tests designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for applications beyond infectious disease.
The expansion into South Asia represents a significant opportunity for Co-Diagnostics to leverage its innovative diagnostic platforms. The CoSara PCR Pro(R) platform is designed to provide rapid, accurate results at the point of care, which is crucial in regions with limited laboratory infrastructure. The SARAGENE(R) product line offers a range of molecular diagnostic tests for various infectious diseases.
For more information about Co-Diagnostics, visit https://co-dx.com/.
The full press release is available at https://ibn.fm/2aATV.
This expansion highlights Co-Diagnostics' commitment to making molecular diagnostics more accessible globally, particularly in underserved regions. With an addressable market of $13 billion, the company is well-positioned to drive growth and improve healthcare outcomes across South Asia.
